Publication:

APP-BP1 Inhibits Aβ42 Levels by Interacting with Presenilin-1

Loading...
Thumbnail Image

Date

2007

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Chen, Yuzhi, Angela M. Bodles, Donna L. McPhie, Rachael L. Neve, Robert E. Mrak, and W. Sue T. Griffin. 2007. APP-BP1 inhibits Aβ42 levels by interacting with Presenilin-1. Molecular Neurodegeneration 2: 3.

Abstract

Background: The β-amyloid precursor protein (APP) is sequentially cleaved by the β- and then γ-secretase to generate the amyloid β-peptides Aβ40 and Aβ42. Increased Aβ42/Aβ40 ratios trigger amyloid plaque formations in Alzheimer's disease (AD). APP binds to APP-BP1, but the biological consequence is not well understood. Results: We report that when the endogenous APP-BP1 was suppressed by small interfering RNAs (siRNAs), cell-associated Aβ42 was dramatically increased in APP695 expressing primary neurons. The accumulation of Aβ42 was accompanied by significant increases in APP and APP-CTF in APP-BP1 siRNA expressing neurons. In contrast, APP-BP1 overexpression in primary neurons significantly decreased the levels of Aβ and endogenous APP but not APLPs. We also investigated the potential mechanism of APP-BP1-mediated APP processing. APP-BP1 co-precipitated with Presenilin-1 (PS1) in native rat brain extracts, co-migrated with the γ-secretase components in brain membrane extracts in glycerol gradient centrifugation, and colocalized in primary neurons. Further, the endogenous PS1-CTF was significantly downregulated by APP-BP1 expression. Conclusion: Our data suggest that APP-BP1 may inhibit Aβ42 production by interacting with PS1 under physiological conditions.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories